180692-27-7

Usage

Uses

Used in Chemical Research:
1-Methyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate is used as a research compound for its potential applications in organic synthesis and material science. Its unique structure and properties make it a valuable tool for exploring new chemical reactions and developing novel materials.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Methyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate is used as a reagent or intermediate for the synthesis of various organic compounds. Its presence of the trifluoromethanesulfonate group allows for versatile reactions and transformations, contributing to the development of new chemical entities.
Used in Material Science:
1-Methyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate is used as a component in the development of new materials with specific properties. Its incorporation into materials can lead to enhanced performance in areas such as electronics, pharmaceuticals, or other advanced technologies.
Note: The specific applications and uses of 1-Methyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate may vary depending on the context and the requirements of the research or industry. The information provided is based on the general understanding of such compounds and their potential uses in chemical research and development.

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 82113-65-3 bis(trifluoromethanesulfonyl)amide 

Downstream Products

• 454482-11-2 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl )-1,2,3,6-tetrahydropyridine 
• 453560-88-8 3-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-trifluoromethyl-phenylamine 
• 442846-96-0 3-(1-methyl-1,2,3,4-tetrahydro-pyridin-4-yl)-5-trifluoromethyl-phenylamine 
• 1426802-47-2 C₂₉H₂₉F₃N₂O₄S*C₂HF₃O₂ 

Relevant academic research and scientific papers

Amino pyrimidine compound and preparation method and application thereof

The invention relates to an amino pyrimidine compound and a preparation method and application thereof. The amino pyrimidine compound has a structure as shown in a formula I. The formula is shown in the description. The compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The invention further relates to a medicine composition comprising the compound, a preparation methodand application thereof in preparation of anti-tumor medicines.

Phthalazine, aza- and diaza-phthalazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Substituted alkylamine derivatives and methods of use

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Structure-activity relationship studies of flavopiridol analogues

Cyclin dependent kinases (CDKs) along with the complementary cyclins form key regulatory checkpoint controls on the cell cycle. Flavopiridol is a synthetic flavone that shows potent and selective cyclin-dependent kinase inhibitory activity. In this paper, we report modifications of the 3-hydroxy-1-methylpiperidinyl (D ring) of flavopiridol and their effect on CDK inhibitory activity. (C) 2000 Elsevier Science. All rights reserved.

Synthesis and monoamine oxidase B catalyzed oxidation of C-4 heteroaromatic substituted 1,2,3,6-tetrahydropyridine derivatives

The monoamine oxidase B (MAO-B) catalyzed oxidation of amines has been proposed to proceed via a polar pathway, an initial single-electron transfer pathway and an initial hydrogen atom transfer pathway. Results from previous studies on selected N-cyclopropyl-4-substituted-1,2,3,6-tetrahydropyridine derivatives have led us to consider a mechanism for these cyclic tertiary allylamines which may not necessarily involve the aminyl radical cation as required by an initial single-electron transfer step. The studies summarized in this paper were undertaken to explore further the structural features that determine the MAO-B substrate and/or inactivator properties of various 1,4-disubstituted tetrahydropyridine derivatives. We report here the results of our studies on the synthesis and MAO-B catalyzed oxidation of 1-methyl- and 1-cyclopropyl-1,2,3,6-tetrahydropyridine derivatives bearing a variety of heteroaromatic groups at C-4. All of the N-cyclopropyltetrahydropyridine analogs were time and concentration dependent inhibitors of MAO-B while all of the N-methyltetrahydropyridine analogs and the N-cyclopropyl-4-(1- methyl-2-pyrryl)tetrahydropyridine analog were substrates. The substrate properties (k(cat)/K(M)) covered a range of 6 to 1800 min-1 mM-1 while the range for the inactivator properties for which k(inact)/K(I) values could be obtained was 0.1-1.0 min-1 mM-1. The partition ratios for the N-cyclopropyl analogs varied from 4 to 17 except for the 4-(1-methyl-2- pyrryl) analog, which had a partition ratio of 400. These results are discussed in terms of the putative allylic radical intermediate and in the context of the hydrogen atom transfer and single-electron transfer based mechanisms.